WallStSmart

Beam Therapeutics Inc (BEAM)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Beam Therapeutics Inc generates 22004% more annual revenue ($164.01M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -40.2%. BEAM earns a higher WallStSmart Score of 35/100 (F).

BEAM

Avoid

35

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 8.5
Piotroski: 5/9Altman Z: 2.47

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BEAM3 strengths · Avg: 9.0/10
Revenue GrowthGrowth
324.9%10/10

Revenue surging 324.9% year-over-year

Debt/EquityHealth
0.229/10

Conservative balance sheet, low leverage

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

BEAM4 concerns · Avg: 2.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
-5.8%2/10

ROE of -5.8% — below average capital efficiency

Free Cash FlowQuality
$-130.75M2/10

Negative free cash flow — burning cash

Profit MarginProfitability
-40.2%1/10

Currently unprofitable

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : BEAM

The strongest argument for BEAM centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 324.9% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : BEAM

The primary concerns for BEAM are EPS Growth, Return on Equity, Free Cash Flow.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

BEAM profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

BEAM carries more volatility with a beta of 2.20 — expect wider price swings.

BEAM is growing revenue faster at 324.9% — sustainability is the question.

BEAM generates stronger free cash flow (-131M), providing more financial flexibility.

Bottom Line

BEAM scores higher overall (35/100 vs 24/100) and 324.9% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Beam Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States. The company is headquartered in Cambridge, Massachusetts.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?